Teva to Launch New Growth Strategy at Investor Day
TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host an Investor Day on Thursday, May 18, 2023 to launch its new growth strategy and portfolio priorities. The event will take place at the New York Stock Exchange in New York City. Presentations will begin at 12:00 p.m. Eastern Time and are expected to conclude at 2:00 p.m. Eastern Time.
Richard Francis, Teva's President and CEO, will detail a strategic framework and key priorities focusing on growth and innovation. Additional members of the executive management team will share insights into key assets that will drive the company’s growth engine, review the Company’s innovative R&D pipeline and discuss efforts to focus the business, as well as outline Teva’s growth and profitability goals.
Due to limited capacity, in-person attendance is by invitation only. Analysts and institutional investors will be invited to pre-register and attend through an invite that will be distributed separately. For questions regarding the event, please contact Teva's Investor Relations team at TevaIR@Tevapharm.com.
A live webcast of the event and presentation materials will be available on Teva's Investor Relations website at: https://ir.tevapharm.com/Events-and-Presentations.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the Investor Day conference and webcast, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our substantial indebtedness; our business and operations in general including: the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2022, including in the sections captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005559/en/
Ran Meir, +1 (267) 468-4475
Yael Ashman, +972 (3) 914 8262
Sanjeev Sharma, +1 (973) 658 2700
Kelley Dougherty, +1 (973) 832-2810
Eden Klein, +972 (3) 906 2645
Source: Teva Pharmaceutical Industries Limited